MedTrace Logo

Evaluation of the Functional Remission Occurrence and Predictive Factors in Schizophrenia

NCT02874560 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 364

Last updated 2018-10-22

No results posted yet for this study

Summary

In a population of patients suffering from schizophrenia being treated for an episode of clinical destabilization and followed for a period of twelve months, the main objective is to evaluate the proportion of patients achieving functional remission and its relationship to clinical remission.

Conditions

Sponsors & Collaborators

  • Janssen-Cilag Ltd.

    lead INDUSTRY

Principal Investigators

  • Janssen-Cilag Ltd. Clinical Trial · Janssen-Cilag Ltd.

Eligibility

Min Age
18 Years
Max Age
37 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-12
Primary Completion
2017-06-30
Completion
2017-07-12

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02874560 on ClinicalTrials.gov